XML 38 R30.htm IDEA: XBRL DOCUMENT
v3.25.3

Revenue from Contracts with Customers (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Revenue from Contract with Customer [Abstract] |
Schedule of Disaggregation of Revenue | The following table summarizes revenue by source as follows:
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(in thousands) |  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Major Products /Service Lines |  |  |  |  |  |  |  |  |  |  |  |
Product revenue, net(1) |  | $ | 376,687 |  |  | $ | 374,601 |  |  | $ | 1,118,152 |  |  | $ | 1,136,670 |
License and royalty revenues |  |  | 7,327 |  |  |  | 4,133 |  |  |  | 16,671 |  |  |  | 6,130 |
Total revenues |  | $ | 384,014 |  |  | $ | 378,734 |  |  | $ | 1,134,823 |  |  | $ | 1,142,800 |
(1) The Company’s product revenue includes PYLARIFY, DEFINITY, Neuraceq and TechneLite among other products. This category represents the delivery of physical goods. The Company applies the same revenue recognition policies and judgments for all its principal products. Revenue by product category on a net basis is as follows:
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(in thousands) |  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
PYLARIFY |  | $ | 240,616 |  |  | $ | 259,756 |  |  | $ | 748,912 |  |  | $ | 791,881 |
Other radiopharmaceutical oncology |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 384 |
Total radiopharmaceutical oncology |  |  | 240,616 |  |  |  | 259,756 |  |  |  | 748,912 |  |  |  | 792,265 |
DEFINITY |  |  | 81,785 |  |  |  | 76,965 |  |  |  | 244,935 |  |  |  | 231,629 |
Neuraceq |  |  | 20,442 |  |  |  | — |  |  |  | 20,442 |  |  |  | — |
TechneLite |  |  | 21,127 |  |  |  | 20,480 |  |  |  | 65,820 |  |  |  | 70,380 |
Other precision diagnostics |  |  | 6,339 |  |  |  | 6,282 |  |  |  | 18,672 |  |  |  | 18,039 |
Total precision diagnostics |  |  | 129,693 |  |  |  | 103,727 |  |  |  | 349,869 |  |  |  | 320,048 |
Strategic partnerships and other revenue |  |  | 13,705 |  |  |  | 15,251 |  |  |  | 36,042 |  |  |  | 30,487 |
Total revenues |  | $ | 384,014 |  |  | $ | 378,734 |  |  | $ | 1,134,823 |  |  | $ | 1,142,800 |

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration